Table 1.
Clinicopathological characteristics of enrolled patients (n = 105).
| Number (Percentage) | Mean ± Standard deviation | |
|
| ||
| Age | Range: 38~81 y/o | 57.69 ± 8.6 |
|
| ||
| Gender: | ||
| Male | 98 (93.3%) | |
| Female | 7 (7.6%) | |
|
| ||
| Pathology | ||
| Squamous cell carcinoma | 105 (100%) | |
|
| ||
| Tumor site | ||
| Upper | 28 (26.7%) | |
| Middle | 48 (45.7%) | |
| Lower | 29 (27.6%) | |
|
| ||
| Stage | ||
| I | 13 (12.4%) | |
| II | 27 (25.7%) | |
| III | 65 (61.9%) | |
|
| ||
| Lab data at diagnosis | ||
| White blood count (/μL) | 7940 ± 2616.9 | |
| Hb (g/dL) | 13.2 ± 1.77 | |
| Platelet count (X103/μL) | 262.82 ± 110.73 | |
| Mean platelet volume (fl) | 9.84 ± 0.83 | |
| Neutrophil (%) | 66.5 ± 11.1 | |
| Lymphocyte (%) | 23.3 ± 9.5 | |
| Monocyte (%) | 6.9 ± 2.6 | |
|
| ||
| Lab data at finished CCRT | ||
| White blood count (/μL) | 3845.7 ± 1832.8 | |
| Hb (g/dL) | 10.9 ± 1.6 | |
| Platelet count (X103/μL) | 174.88 ± 81.1 | |
| Mean platelet volume (fl) | 9.35 ± 0.92 | |
| Neutrophil (%) | 79.7 ±11.2 | |
| Lymphocyte (%) | 9.4 ± 7.9 | |
| Monocyte (%) | 8.5 ± 5 | |
|
| ||
| Chemotherapy cycles | ||
| 2 cycles | 96 (91.4%) | |
| 1 cycle | 9 (8.6%) | |
|
| ||
| Radiotherapy | 105 (100%) | |
| Dose 4000 ~ 5000cGy | 40 (38.1%) | |
| Dose > 5000cGy | 65 (61.9%) | |
|
| ||
| Post-CCRT response | ||
| Complete response | 38 (36.2%) | |
| Partial response | 48 (45.7%) | |
| Stable disease | 2 (1.9%) | |
| Progressive disease | 17 (16.2%) | |
| Overall response | 86 (81.9%) | |
| Clinical benefit | 88 (83.8%) | |
|
| ||
| Post-CCRT treatment | ||
| Operation | 38 (36.2%) | |
| Chemotherapy | 45 (42.9%) | |
| Non-treatment | 22 (20.9%) | |
|
| ||
| Expired | 56 (53.3%) | |
| Overall survival (days) | (92~1844 days) | 586 ± 423.5 |
|
| ||
| Progressive rate | 62 (59%) | |
| Time to progressive disease (days) | 414.6 ± 355.5 | |
|
| ||
| Metastatic rate | 56 (53.3%) | |
| Time to metastasis (days) | 425.8 ± 356.8 | |